Premium
Physical characterization of controlled release of paclitaxel from the TAXUS™ Express 2 ™ drug‐eluting stent
Author(s) -
Ranade Shrirang V.,
Miller Kathleen M.,
Richard Robert E.,
Chan A. Ken,
Allen Michael J.,
Helmus Michael N.
Publication year - 2004
Publication title -
journal of biomedical materials research part a
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.849
H-Index - 150
eISSN - 1552-4965
pISSN - 1549-3296
DOI - 10.1002/jbm.a.30188
Subject(s) - materials science , coating , chemical engineering , polymer , paclitaxel , drug delivery , miscibility , composite material , nanotechnology , surgery , medicine , chemotherapy , engineering
Abstract The polymer carrier technology in the TAXUS™ drug‐eluting stent consists of a thermoplastic elastomer poly(styrene‐ b ‐isobutylene‐ b ‐styrene) (SIBS) with microphase‐separated morphology resulting in optimal properties for a drug‐delivery stent coating. Comprehensive physical characterization of the stent coatings and cast film formulations showed that paclitaxel (PTx) exists primarily as discrete nanoparticles embedded in the SIBS matrix. Thermal and chemical analysis did not show any evidence of solubility of PTx in SIBS or of any molecular miscibility between PTx and SIBS. Atomic force microscope data images revealed for the first time three‐dimensional stent coating surfaces at high spatial resolutions in air and in situ under phosphate‐buffered saline as drug was released. PTx release involves the initial dissolution of drug particles from the PTx/SIBS coating surface. Morphological examination of the stent coatings in vitro supported an early burst release in most formulations because of surface PTx followed by a sustained slower release of PTx from the bulk coating. The in vitro PTx release kinetics were dependent on the formulation and correlated to the drug‐to‐polymer ratio. Atomic force microscopy analysis confirmed this correlation and further supported the concept of a matrix‐based drug‐release coating. © 2004 Wiley Periodicals, Inc. J Biomed Mater Res 71A: 625–634, 2004